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Conclusions Both MTD and RD of NC-6004 were deter-
mined to be 90 mg/m2. The pharmacodynamic (PD) model 
well explained the time course of estimated glomerular 
filtration rate (eGFR) and amplitude of decrease in eGFR. 
The decrease in eGFR appeared to reach saturation at 
>100 mg/m2 with NC-6004. Estimated probability of acute 
kidney injury on this PK/PD simulation was 30% with 
NC-6004 and 70% with cisplatin, which may better explain 
the renal toxicity profile.
Keywords Acute kidney injury · Cisplatin · Micelles · 
Population PK/PD analysis · NC-6004
Abbreviations
PK  Pharmacokinetic
AKI  Acute kidney injury
PD  Pharmacodynamic
eGFR  Estimated glomerular filtration rate
KDIGO  Kidney disease: improving global outcomes
DLT  Dose-limiting toxicity
Pt  Plasma total platinum
ICP  Inductively coupled plasma
Introduction
NC-6004 is a novel micellar nanoparticle product of cispl-
atin, approximately 30 nm in diameter, obtained by cross-
linking with a polyethylene glycol–poly glutamic acid 
block copolymer. Early basic research has indicated that 
when compared with conventional cisplatin, encapsulat-
ing cisplatin in the micellar nanoparticle can selectively 
improve accumulation at the tumor site. Indeed, NC-6004 
progressively breaks down in the presence of chloride to 
release cisplatin slowly, and this slow release helps achieve 
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longer systemic exposure that contributes to continuous 
and potentially improved antitumor effects. Cytotoxicity 
from NC-6004 is expected based on the formation of cel-
lular DNA adducts with the released cisplatin.
Preliminary nonclinical studies have indicated several 
beneficial characteristics of NC-6004: (1) preferential dis-
tribution to tumors, (2) significantly lower toxicity com-
pared with cisplatin at equivalent doses, and (3) increased 
antitumor activity [1]. The enhanced permeability and 
retention associated with polymeric micelles mean that 
the formulation benefited from extended blood circulation 
and selective and higher accumulation at the tumor site 
[2]. These clinical characteristics of NC-6004 have been 
demonstrated in both a phase I study where NC-6004 was 
used in monotherapy for patients with solid tumors in the 
UK (the NC-6004-001 study) and a phase I/II study where 
NC-6004 was used in combination with gemcitabine in 
patients with pancreatic cancer in Taiwan and Singapore 
(the NC-6004-002 study).
The present study was designed with two aims: (1) to 
assess the tolerability of NC-6004 in combination with 
gemcitabine in Japanese patients with solid tumors and 
(2) to obtain pharmacokinetic (PK) and pharmacodynamic 
(PD) data for NC-6004 monotherapy in Japanese patients.
Materials and methods
Study design
This study was an open-label phase I study to confirm the 
safety and tolerability of NC-6004 in combination with 
gemcitabine in Japanese patients with advanced solid 
tumors and to assess the PK effects of NC-6004 mono-
therapy. The study schedule comprised a screening phase, 
an NC-6004-alone phase, an NC-6004-plus-gemcitabine 
combination phase, and a follow-up phase. The study was 
conducted according to the provisions of the Declaration of 
Helsinki and the Guidelines for Good Clinical Practice, and 
was approved by the relevant institutional review board. 
Written informed consent was obtained from all patients 
before inclusion.
Patient selection
Japanese patients with treatment-refractory solid tumors were 
recruited. Inclusion criteria were as follows: (1) age between 
20 and 75 years, (2) histologically or cytologically con-
firmed cancer, (3) evaluable tumor lesions according to the 
Response Evaluation Criteria in Solid Tumors guideline (Ver-
sion 1.1), (4) Eastern Cooperative Oncology Group perfor-
mance status 0 to 2, and (5) adequate bone marrow reserve at 
screening. The exclusion criteria were as follows: (1) known 
hypersensitivity to platinum compounds or gemcitabine; 
(2) previous therapy with more than two different platinum-
based regimens, or a regimen with a cumulative dose exceed-
ing 480 mg/m2 for cisplatin, 1040 mg/m2 for oxaliplatin, or 
42  mg/mL/min for carboplatin (cumulative area under the 
curve); (3) previous chemotherapy or radiotherapy within 
28 days before the study treatment; (4) a history of sympto-
matic pulmonary fibrosis or interstitial pneumonia, with obvi-
ous evidence on a plain X-ray of the chest; (5) previous chest 
radiotherapy; (6) diagnosed chronic kidney disease defined 
as an estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2; and (7) greater than grade 2 auditory toxicity by 
pure tone audiometry or greater than grade 2 neurotoxicity.
Dosing rationale
Although the MTD was not determined during the 
NC-6004-001 phase I study in the UK, the RD was sug-
gested to be close to 90 mg/m2 for monotherapy. The RD of 
NC-6004 given with gemcitabine has also been estimated to 
be 90 mg/m2 based on the phase I part of the NC-6004-002 
study in Asia. From those results, the RD of NC-6004 in the 
Japanese patient population has been estimated at 90  mg/
m2; however, in this study we initiated dosing at 60 mg/m2, 
and NC-6004 was mixed in 250 mL of 5% dextrose solution 
and given intravenously for over 60 min daily for 21 days. 
Oral dexamethasone; normal saline solution, including KCl 
and MgSO4; diphenhydramine hydrochloride; ranitidine; 
and mannitol were also provided as a prophylactic treat-
ment for hypersensitivity before and after each treatment 
cycle. Treatment could be continued until eight cycles over 
24 weeks, with the patient observed until 28 days after the 
eighth cycle or until discontinuation of the study treatment.
Protocol: determination of the MTD and RD
The administration of NC-6004 alone was started at 60 mg/
m2 every treatment cycle (21 days per cycle). From the 
second through eighth cycles, patients received NC-6004 
in combination with 1,000 mg/m2 of gemcitabine that was 
administered on day 1 and day 8 of each cycle, except for 
the first treatment cycle.
Three patients were expected to be enrolled in the 
NC-6004 60 mg/m2 cohort. When a dose-limiting toxicity 
(DLT) event was observed, another three patients would be 
added to assess safety. A maximum of nine patients could 
be enrolled, as necessary, to obtain further safety informa-
tion in this cohort. If two of the six or nine patients reached 
a DLT event at 60  mg/m2, that was considered the MTD. 
After evaluating safety for all patients, including at least 
two cycles of the study treatment, the first patient in the 
next 90 mg/m2 cohort was enrolled. Subsequent dose esca-
lations were planned to doses of 120 or 150 mg/m2 in the 
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same manner. The MTD was defined as the dose at which 
two of the six or nine patients experienced DLT. The RD 
was defined as the dose one level lower than the MTD; how-
ever, in all cases, the MTD or RD was only confirmed after 
discussion between the sponsor and the medical expert.
DLT was defined as follows: (1) grade 4 hematologic 
toxicity; (2) grade 3 thrombocytopenia with bleeding; (3) 
grade 3 or greater neutropenia with fever over 38.5 °C or 
with grade 2 or greater diarrhea; (4) grade 3 or greater neu-
tropenia without fever for at least five days; (5) grade 3 or 
greater non-hematologic toxicity (except alopecia, treatable 
nausea or emesis, and biochemistry abnormalities without 
specific symptoms); (6) treatment delay of greater than two 
weeks before the start of the next treatment cycle (NC-6004 
or gemcitabine) due to unresolved toxicity; (7) grade 3 or 
greater hypersensitivity reaction; (8) an eGFR toxicity of 
30–59 mL/min/1.73  m2 delaying dosing by more than 14 
days; or (9) an eGFR <30 mL/min/1.73  m2, or apparent 
renal failure identified by another index.
Statistical analysis
Data were not tested statistically because this phase I study 
focused on safety and tolerability, estimation of the RD, 
and collection of PK data, except in the case of the popula-
tion analysis.
Population analysis
All population analyses were performed by NONMEM 
ver. 7.3.0, using the FOCE INTER estimation method. A 
difference of 7.879 in the value of the objective function 
(ΔOFV) with one degree of freedom was defined as being 
statistically significant (P < 0.005). A proportional model 
was selected for the residual error and inter-individual vari-
ability for the stochastic model.
Population PK analysis
Blood samples for PK analysis were taken immediately 
before dosing, just after dosing, and at 1, 3, 6, 24, 48, 72, 
168, 336, and 504 h after dosing. A population PK analysis 
was then performed using data obtained in this study that 
were merged with those from the phase I study performed 
by NanoCarrier Co., Ltd. in the UK (NC-6004-001 study).
The plasma total platinum (Pt) concentration was meas-
ured by the inductively coupled plasma (ICP) method in 
this study. In the previous UK study, plasma total Pt con-
centration was measured by both ICP and atomic absorp-
tion spectroscopy (AA) methods. Outlier data were not 
excluded from the analysis. In this PK analysis, the ratio 
of values between ICP and AA had an intra-individual dis-
tribution and the AA value was converted to an ICP value.
Two compartments with a first-order elimination model 
were selected for PK structural model. A proportional 
model was selected for the residual error and inter-individ-
ual variability as the stochastic model.
As the possible/available covariates, baselines of body 
weight and eGFR and ethnic difference were selected. 
Clearance and volume of distribution might be influenced 
by these covariates.
First, all possible combinations of covariates and PK 
parameters were included in the base model, and non-sig-
nificant covariates were then excluded. The models includ-
ing all significant covariates were tested for each covariate, 
and the significant covariates remained in the final model.
Population PK/PD analysis
A population PK/PD model for eGFR was built with an 
empirical indirect model of Model I [3], using the follow-
ing equation for the eGFR time course:
where  GFR0 is the baseline GFR, Imax is the maximum 
inhibition (0 < Imax < 1),  kin is  eGFR0 × Kout,  IC50 is the con-
centration to achieve 50% inhibition, and Cf is the plasma-
free Pt concentration.
Individual  Cf was derived from population PK analy-
sis. Most of the PK/PD parameters were assumed to be 
proportional to exp(η) with η assumed to be normal with 
a mean of 0. As shown in Fig.  1, the amplitude of the 
eGFR decrease after starting NC-6004 seemed to reduce 
with repeated administration. Therefore, Imax was assumed 
to decrease through repeated administrations and was 
expressed as follows:
where i, j, and k represent the subject, measurement time, 
and occasion (i.e., the period through kth to [k + 1]th 
administration). Inter-occasional variability (IOV) was also 
assumed because some patients showed the largest eGFR 
decrease after a later administration rather than after the 
first administration.
During and after model building, simulations were done. 
The serum creatinine (sCr) simulation was done by calculat-
ing the eGFR using the Cockcroft–Gault equation in both 
clinical studies, with the increase of sCr ratio from base-
line being required to be the same as the decrease in the 
eGFR ratio within a subject (i.e., an inverse relation within 
a patient). The mean and standard deviation for the baseline 
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used for the sCr simulation on day 7, which was 6 days after 
the first administration.
Renal dysfunction severity was calculated for each vir-
tual subject according to the Kidney Disease: Improving 
Global Outcomes (KDIGO) definition: stage 1 = 0.3  mg/dL 
increase from or 1.5–1.9 times the pretreatment value; stage 
2 = 2.0–2.9 times the pretreatment value; and stage 3 = ≥3.0 
times the pretreatment value or the sCr increase >4.0 mg/dL 
from the pretreatment value [4].
Results
Patient characteristics
The patients’ demographics are summarized in Table  1. 
The mean age of the ten male and two female patients was 
59.5 years, ranging from 34 to 72 years. In total, seven 
patients had carcinoma and five patients had neuroendo-
crine tumor. Eight patients were classified as stage IV, and 
four patients were not classified. All patients had metastatic 
lesions. The most common site of metastasis was the lymph 
nodes, followed by the liver. All patients had a previous 
history of chemotherapy, and seven patients had received 
cisplatin treatment. One patient had undergone a previous 
gemcitabine treatment. The maximum cumulative dose of 
cisplatin was 420 mg/m2. Six patients had a history of sur-
gery, and three had a history of radiotherapy.
Safety analysis
Patients were planned to receive NC-6004 at the doses of 
60, 90, 120, and 150 mg/m2 but were actually treated with 
only 60 and 90 mg/m2 doses because of the development 
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Fig. 1  Example of individual time course for the estimated glomeru-
lar filtration rate. Circle shows the observed value, and curve shows 
the model-predicted time course. Dotted line shows the administra-
tion of NC-6004 (dotted lines administration). eGFR estimated glo-
merular filtration rate
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of the grade 3 or 4 drug-related toxicities, as shown in 
Table 2. Grade 3 or greater adverse events (AEs) related to 
NC-6004 included a neutrophil count decrease in the (two 
patients: 66.7%) 60 mg/m2 cohort and (six patients: 66.7%) 
90  mg/m2 cohort and a decreased white blood cell count 
in the (four patients: 44.4%) 90 mg/m2 cohort. At least one 
AE related to NC-6004 was observed in all 12 patients in 
the safety evaluation cohort. Events in which the incidence 
was more than 40% were neutropenia (10 patients: 83.3%), 
leukopenia (10 patients: 83.3%), and thrombocytopenia 
(nine patients: 75.0%).
The DLTs in each cohort were counted during the 
NC-6004 monotherapy phase (cycle 1) and the NC-
6004-plus-gemcitabine combination phase (cycle 2). No 
DLTs occurred in the 60  mg/m2 cohort of three patients, 
but four DLTs were observed in the 90  mg/m2 cohort of 
nine patients. In total, four of 12 patients experienced DLT: 
three patients experienced grade 4 hematologic toxicities, 
and one patient experienced a non-hematologic toxicity (an 
eGFR <30 mL/min/1.73 m2). After observing the effect on 
eGFR, the study protocol was amended to add prophylac-
tic hydration therapy [5] before and after treatment with 
NC-6004 to prevent renal toxicity. Seven patients did not 
receive hydration therapy, and other five patients did. No 
renal toxicity occurred among the patients who received 
hydration therapy. Based on these findings, the MTD and 
RD of NC-6004, when given in combination with gemcit-
abine, were both determined to be 90 mg/m2, with the latter 
being decided after discussion with the study sponsor.
Efficacy analysis
One patient showed partial response and eight patients 
had stable disease. The objective response rate and disease 
control rate were 9.1 and 81.8%, respectively. Patient sur-
vival beyond 18 months after the first dose was analyzed 
by Kaplan–Meier survival curves. The curve reached a 50% 
survival level by day 327, which persisted until day 596 
(i.e., the final follow-up day).
Population PK analysis
The number of subjects included for PK analysis was 12 
from this study and 17 from the UK study, resulting in a 
total of 546 observed concentrations for the final analysis. 
The total plasma Pt concentration was measured by the ICP 
method in all 12 patients in this study (108 points), while 
in the UK study total plasma Pt concentration was meas-
ured by the ICP method in five patients (42 points) and 
by the AA method in 17 patients (144 points). Notably, in 
the five patients whose total plasma Pt concentration was 
measured by both ICP and AA, the AA values were almost 
70% higher than the ICP values, so the data obtained by 
Table 1  Patient demographics (safety population)
ECOG Eastern Cooperative Oncology Group
Characteristics Cohort Total (%)
60 mg/m2 (%) 90 mg/m2 (%)
Age (year)
 Number 3 9 12
 Mean ± SD 46.3 ± 13.7 63.9 ± 7.5 59.5 ± 11.7
 Median 44 66 65
 Range 34–61 46–72 34–72
Gender
 Male 2 (66.7) 8 (88.9) 10 (83.3)
 Female 1 (33.3) 1 (11.1) 2 (16.7)
Tumor type
 Sarcoma 0 (0.0) 0 (0.0) 0 (0.0)
 Carcinoma 1 (33.3) 6 (66.7) 7 (58.3)
 Lymphoma 0 (0.0) 0 (0.0) 0 (0.0)
 Other 2 (66.7) 3 (33.3) 5 (41.7)
Metastatic sites (multi-choice)
 Adrenal 0 (0.0) 0 (0.0) 0 (0.0)
 Liver 3 (100.0) 4 (44.4) 7 (58.3)
 Bone 1 (33.3) 0 (0.0) 1 (8.3)
 Lymph nodes 3 (100.0) 5 (55.6) 8 (66.7)
 Lung 1 (33.3) 2 (22.2) 3 (25.0)
 Skin/soft tissue 0 (0.0) 0 (0.0) 0 (0.0)
 Other 1 (33.3) 4 (44.4) 5 (41.7)
 N/A 0 (0.0) 0 (0.0) 0 (0.0)
Stage
 III 0 (0.0) 0 (0.0) 0 (0.0)
 IIIA 0 (0.0) 0 (0.0) 0 (0.0)
 IIIB 0 (0.0) 0 (0.0) 0 (0.0)
 IV 3 (100.0) 5 (55.6) 8 (66.7)
Previous cancer treatment
 Surgery
  No 2 (66.7) 4 (44.4) 6 (50.0)
  Yes 1 (33.3) 5 (55.6) 6 (50.0)
 Chemotherapy
  No 0 (0.0) 0 (0.0) 0 (0.0)
  Yes 3 (100.0) 9 (100.0) 12 (100.0)
 Radiotherapy
  No 2 (66.7) 7 (77.8) 9 (75.0)
  Yes 1 (33.3) 2 (22.2) 3 (25.0)
 Other therapies
  No 3 (100.0) 8 (88.9) 11 (91.7)
  Yes 0 (0.0) 1 (11.1) 1 (8.3)
ECOG performance status
 0 2 (66.7) 5 (55.6) 7 (58.3)
 1 1 (33.3) 4 (44.4) 5 (41.7)
 2 0 (0.0) 0 (0.0) 0 (0.0)
Hydration
 With – 5 (55.6) 5 (41.7)
 Without 3 (100.0) 4 (44.4) 7 (58.3)
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the AA method were converted to ICP values. The plasma-
free Pt concentration was also measured in 28 patients (252 
points). The selected population PK model was confirmed 
to explain the NC-6004 PK profile (free concentration also 
showed a good fit, but the data are not shown).
The PK parameters in the final model are summarized 
in Table  3. During covariate selection, the influence of 
ethnic difference on clearance was evaluated to have a 
ΔOFV of 0.014 (P = 0.906). However, the influences of 
body weight on the clearance and central volume of dis-
tribution were significant. Clearance and central volume 
of distribution increased in proportion to around the 0.7th 
power for body weight increase, as observed with other 
drugs. This has also become a good rationale of dose 
adjustment by body surface area. The typical central vol-
ume of distribution was 2.69 L, which was smaller than 
the blood volume. Therefore, most of the administered 
NC-6004 was thought to be captured within vessels just 
after administration. The peripheral volume of distribu-
tion was 3.91 L and the amount of NC-6004 transferred 
to peripheral tissue was considered to be limited. There-
fore, this drug should be barely transferable to some vul-
nerable tissues. Finally, the clearance of NC-6004 was 
estimated at 0.0687 L h, corresponding to 1/100th of the 
normal GFR value, meaning that NC-6004 should be sta-
ble in the human body.
Population PK/PD analysis
The estimated population PK/PD parameters are shown in 
Table  4. The number of subjects for the PK/PD analysis 
was 12 (mean 8.1 points/subject) from this study and 17 
Table 2  Grade 3 or 4 
NC-6004-related adverse events
MedDRA Medical Dictionary for Regulatory Activities, SOC System Organ Class, PT preferred terms
MedDRA SOC MedDRA PT 60 mg/m2, N = 3 90 mg/m2, N = 9
Investigations Gamma-glutamyltransferase decreased 0 (0.0) 1 (11.1)
Investigations Neutrophil count decreased 2 (66.7) 6 (66.7)
Investigations Platelet count decreased 1 (33.3) 1 (11.1)
Investigations White blood cell count decreased 1 (33.3) 4 (44.4)
Metabolism and 
nutrition disorders
Hypokalemia 0 (0.0) 1 (11.1)
Table 3  Estimated population 
PK parameters (the final model)
Mean (90% CI)
CL clearance, V1 central volume of distribution, V2 volume of distribution, CV% coefficient of variation, 
ICP inductively coupled plasma method, AA atomic absorption spectroscopy
a The typical value at 67.8 kg of body weight




 TV1a (L) 2.69 (2.39–2.99) 13.9 (7.3–18.2)
 Θ(V1−WT): V1 = TV1× (WT/67.8) Θ 0.763 (0.412–1.11) –
 V2† (L) 3.91 (2.80–5.02) –
 CL (L/h) 0.0687 (0.0615–0.0759) 17.2 (8.9–22.7)
 Θ(CL−WT): CL = TCL× (WT/67.8) Θ 0.731 (0.346–1.115) –
 Q (L/h) 0.0117 (0.0096–0.0138) 20.1 (0–28.5)
 Vm1 (L) 81.6 (69.7–93.5) 24.4 (0–36.5)
 Vm2 (L) 665 (549–781) 42.4 (24.2–54.9)
 CLm (L/h) 6.54 (5.56–7.52) 45.7 (21.8–60.9)
 Qm (L/h) 9.30 (5.73–12.87) 54.4 (22.2–73.7)
 Difference by method [folds] (AA to ICP) 1.69 (1.41–1.97) 21.2 (4.8–29.6)
Intra-individual variability
 Total Pt (ICP) (CV%) 17.0 (15.2–18.7)
 Total Pt (AA) (CV%) 31.6 (27.5–35.3)
 Free Pt (ICP) (CV%] 31.6 (24.0–37.7)
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(mean 13.7 points/subject) from the UK study (NC-6004-
001 study).
The decrease in eGFR (%) distribution per dose level 
was simulated and compared with the observed eGFR 
decrease. As shown in Fig. 2, most observed values were 
captured within 80% confidence intervals (CIs). The esti-
mated Kout suggests that the injured kidney function 
(eGFR) recovered to half the damage level by 4 days and 
that there was a relatively large difference in this recovery 
speed among patients [inter-individual coefficient of varia-
tion (CV%) of 48%].
The population mean of  IC50 (i.e., the concentration of 
free Pt that causes half of the maximum damage) was esti-
mated at 35.3 ng/mL. There was a huge variability in the 
Table 4  Estimated population pharmacokinetic/pharmacodynamic 
model parameters
GFR0 baseline GFR; Imax maximum inhibition (0 < Imax < 1); IC50 the 
concentration to achieve 50% inhibition; GFR, glomerular filtration 
rate
Parameter Population mean Inter-individual 
variance (CV%)
GFR0 (mL/min/1.73 m2) 83.4 26.5
Kout (/day) 0.171 48.7
IC50 (ng/mL) 35.3 211.7
Imax0 0.851 –
Imax decrease trend (/day) 0.0273 –
IOV (Imax) (CV%) 53.1
Intra-individual variance (CV%) 8.8






























































































































Fig. 2  Model prediction showing 80% confidence intervals (CIs) for 
change in estimated glomerular filtration rate and the observed val-
ues. Curves show 90% and 10% quintiles and the median simulated 
values, with the dotted lines showing the administration timings. 
Abbreviations: eGFR, estimated glomerular filtration rate
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 IC50 value, with a CV% of 211.7, meaning that there was a 
very broad range of susceptibility to free Pt exposure. The 
 IC50 and  Kout values did not change with several sensitive 
analyses (data not shown).
The value of Imax decreased with repeated administration 
of NC-6004, such that the patients became increasingly tol-
erant with the Imax decreasing to half by day 25.4. The IOV 
was assumed in the PK/PD model and remained symmetrical 
over time (data not shown). The effect of hydration therapy 
was evaluated preliminarily and was shown to be associated 
with a ΔOFV decrease by 2.556 (P < 0.110). The small num-
ber of patients (only five) precluded evaluation of its effect.
The hypothesis of Imax=1 was evaluated preliminarily, 
and the ΔOVF decreased by 1.77 (P < 0.183). However, the 
IOV for  Imax was necessary and fixing  Imax to 1 was thought 
not to be appropriate. The estimated 90% CI did not include 
one; however, it was decided that  Imax<1 should remain in 
the model.
Figure  3 shows the correlation between the individual 
model prediction for eGFR and the observed eGFR. There 
was a good correlation, meaning that the model could suf-
ficiently describe the decrease in eGFR after NC-6004 
administration. There was no bias or symmetry over time 
in the weighted residuals (data not shown), so it was con-
cluded that the model described the eGFR changes without 
bias for the whole period.
Simulation of provability of acute kidney injury 
between NC-6004 and cisplatin
The effect of cisplatin on acute kidney injury (AKI) was 
previously reported in patients with head and neck cancer 
[4]. All patients had received hydration in that study and 
the mean cisplatin dose was 99 ± 9  mg/m2. According 
to the KDIGO definition of severity, of the 233 included 
patients, 158 (68%) developed AKI; among these, 77 (49%) 
developed stage 1 AKI, 55 (35%) developed stage 2 AKI, 
and 26 (16%) developed stage 3 AKI.
The simulation results for NC-6004 at a dose of 
100  mg/m2 dose are compared with these results [4] in 
Fig. 4. Almost 70% of patients who received 100 mg/m2 
of NC-6004 did not show AKI, and this ratio was dou-
ble that shown with cisplatin. By comparison, the most 
common AKI grade was stage 1 with cisplatin treatment, 
with cisplatin causing a proportionally greater number of 
cases with AKI as the stage increased, when compared 
with NC-6004 (there were very few cases with stage 3 
AKI). Although the percentage of patients with no AKI 
became less than 60% at an NC-6004 dose of 200 mg/m2, 
there were still few cases with stage 3 AKI and the over-
all safety profile did not change substantially from that for 
the 100 mg/m2 dose.













Correlation between observed and model predicted eGFR







































Fig. 3  Observed data vs. individual predicted data and weighted residuals vs. time for estimated glomerular filtration rate. eGFR estimated glo-
merular filtration rate, IPRED individual predicted data, DV observed data, WRES weighted residuals




The safety profile of NC-6004 was expected to be similar 
to that of cisplatin. Therefore, neural, auditory, renal, and 
hematologic toxicity were considered potential AEs of 
NC-6004.
Concerning the occurrence of renal toxicity, sCr 
increased in two patients (16.7%; one given 60 mg/m2 and 
one given 90 mg/m2). Renal disorder was also observed in 
two patients in the 90  mg/m2 cohort (16.7%), with renal 
impairment occurring in one patient in the 90 mg/m2 cohort 
(8.3%). These renal effects were all considered related to 
NC-6004. But after adding prophylactic hydration therapy 
before and after treatment with NC-6004, no further renal 
toxicity events occurred. The detail of the renal toxicity 
profile was revealed by population PK/PD analysis, which 
confirmed that the frequency and severity of AKI were 
much lower than those reported for cisplatin.
There was evidence of hematologic toxicity, with neu-
tropenia being observed in 10 patients (83.3%; three given 
60 mg/m2 and seven given 90 mg/m2), thrombocytopenia in 
nine patients (75.0%; three given 60 mg/m2 and six given 
90  mg/m2), and leukopenia in 10 patients (83.3%; three 
given 60 mg/m2 and seven given 90 mg/m2). Causality was 
attributed to NC-6004 for all of these events. However, no 
cases of neutropenia or thrombocytopenia were observed in 
the NC-6004 monotherapy phase, with both only occurring 
later the next day after starting gemcitabine. According 
to its package insert, myelosuppression is the most com-
mon AE with gemcitabine [6], and the package insert for 
cisplatin also states that myelosuppression may occur dur-
ing treatment [7]. Hematologic toxicities that more than 
doubled in incidence between cycle one and cycle two 
and were experienced by at least two patients were ane-
mia, neutropenia, thrombocytopenia, and leukopenia in the 
60  mg/m2 cohort and hemoglobin decrease, neutropenia, 
thrombocytopenia, and leukopenia in the 90 mg/m2 cohort.
Although a grade 1 peripheral nerve disorder was 
observed in one patient (8.3%), this neurotoxicity was not 
considered to be related to NC-6004. Hypersensitivity was 
also observed in one patient (8.3%), but was judged to be 
an allergic reaction to the transfusion, and not to NC-6004. 
In addition, no auditory toxicity was observed. Adverse 
reactions showed the same pattern as AEs. Finally, six 
patients (50.0%) from the safety population died within the 
18-month follow-up period after the first dose. All of the 
deaths were considered to be caused by disease progression 
and were judged to be unrelated to NC-6004.
Dosing: justification of the MTD and RD
The MTD and RD of NC-6004 were determined to be 90 
and 60 mg/m2, respectively, based on the protocol criteria. 
However, the RD was determined to be 90 mg/m2 for the 
following reasons after further discussion with the spon-
sor: (1) three of the four observed DLTs were considered 
typical, manageable hematologic toxicities of gemcitabine 
or cisplatin, and (2) the remaining DLT of cisplatin was 
shown to be controllable by prophylactic hydration.
Population PK and PK/PD analyses
The PK profile of NC-6004 was not influenced by ethnic-
ity, i.e., difference between Japanese and Caucasians with 
population PK analysis.
The PK/PD model also explained the time course for 
eGFR after the first dose, as well as the significant decrease 
in amplification after repeated administrations. The eGFR 
decrease was thought to reach saturation at 100  mg/m2. 
Finally, although cisplatin had been reported to cause AKI 
in almost 70% of patients, the PK/PD simulation indicated 
that NC-6004 caused AKI in only 30% of patients. Most 
patients showed stage I AKI overall, but while there were 
high levels of stage II and III AKI with cisplatin, the dis-
tribution of AKI shifted in favor of no AKI or milder AKI 
with NC-6004 therapy.
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Fig. 4  Comparison of acute kidney injury between NC-6004 and 
cisplatin. Patients (%) are shown by acute kidney injury (AKI) stage 
(black bar) for cisplatin (99 ± 9  mg/m2) on days 3–4 [4] and (gray 
bar) as simulated for NC-6004 (100 mg) on day 6
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